CORRECTED: Celsion Corporation to present at the Healthcare Robins Roadshow.Business Editors Healthcare Robins Roadshow Equity Conference COLUMBIA, Md.--(BUSINESS WIRE)--June 8, 2004 Celsion Corporation (AMEX AMEX See: American Stock Exchange :CLN CLN Clean CLN Community Learning Network CLN Colon CLN Celsion Corporation CLN Class Library for Numbers CLN Credit Linked Note CLN Comitato di Liberazione Nazionale (Committee of National Liberation) CLN Corn Lethal Necrosis ), will be presenting at the Healthcare Robins Roadshow Equity Conference. June 10, 2004, at 8:00 a.m. Eastern Time This conference presentation is being webcast by Thomson/CCBN and can be accessed at Robins Media Group's web site at www.robinsmediagroup.com/healthcare The webcast is also being distributed over Thomson/CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson/CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in Thomson/CCBN's Individual Investor Network. Institutional investors can access the call via Thomson/CCBN's password-protected event management site, StreetEvents (www.streetevents.com). Celsion Corporation is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused heat energy, either administered alone or in combination with other therapeutic devices, heat-activated genes and heat-activated drugs. The Company's Prolieve(TM) Thermodilatation system was recently approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the treatment of benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. . In addition, it is in active clinical development of a system using its adaptive phased array focused microwave technology to treat breast cancer and heat-activated liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. technology to deliver chemotherapeutic drugs for the treatment of prostate and liver cancer. In addition, the Company's gene-based cancer repair inhibitor, licensed from Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New , is in late- stage animal testing. The conference will be moderated by Marc Robins, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. , the founder of Catalyst Financial Resources and founder of The Red Chip Review. Marc has 25 years of experience in capital markets. Experience which includes a regularly featured column in Forbes, contributed articles in the AAII AAII See: American Association of Individual Investors Journal and his frequent quotes found in various financial media. The conference is part of a series of Robins Roadshows provided by Robins Media Group and Catalyst Financial Resources. These Roadshows place small-cap companies before a professional audience of buy-side, sell-side analysts, portfolio managers, research directors, and chief investment officers whose investment styles are relative to the profiles of the presenting companies. Also appearing and delivering the keynote address will be Blair Childs, Executive Vice President of Strategic Planning and Implementation for AdvaMed. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion